Drugs / IBCASERTIB
Trials 17 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT05346601 | Jun 2022 | — | Chipscreen Biosciences, Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03216343 | Nov 2017 → Nov 2022 | small cell lung carcinoma | Chipscreen Biosciences, Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03074825 | May → Aug 2017 | non-Hodgkin lymphoma | Chipscreen Biosciences, Ltd. | Terminated | No outcome recorded |
| Phase 1 | NCT02122809 | Feb 2014 → Apr 2016 | cancer | Chipscreen Biosciences, Ltd. | Completed | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT05271292 | Aug 2022 → Mar 2025 overdue | small cell lung carcinoma | Chipscreen Biosciences, Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05505825 | Aug 2022 → Jul 2024 | small cell lung carcinoma | Akeso | Completed | No outcome recorded |
| Phase 1/2 | NCT03974243 | Jul 2019 → Dec 2021 | non-Hodgkin lymphoma | Chipscreen Biosciences, Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT03245190 | Apr 2018 → Nov 2019 | hepatocellular carcinoma | Chipscreen Biosciences, Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT03166891 | Dec 2017 → Mar 2019 | ovarian cancer | Chipscreen Biosciences, Ltd. | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT06492915 | Aug 2024 → May 2026 overdue | pancreatic ductal adenocarcinoma | Chipscreen Biosciences, Ltd. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05497843 | Aug 2022 → Jan 2025 | soft tissue sarcoma | Chipscreen Biosciences, Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT05336721 | Nov 2021 → Oct 2024 | triple-negative breast carcinoma | Chipscreen Biosciences, Ltd. | Terminated | No outcome recorded |
| Phase 2 | NCT03901118 | Jul 2019 → Dec 2020 | ovarian cancer | Chipscreen Biosciences, Ltd. | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT07445295 | Mar 2026 → Jun 2028 expected | pancreatic ductal adenocarcinoma | Chipscreen Biosciences, Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT04921527 | Dec 2021 → Dec 2024 overdue | ovarian cancer | Chipscreen Biosciences, Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT04830813 | Mar 2021 → Apr 2024 | small cell lung carcinoma | Chipscreen Biosciences, Ltd. | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05371899 | Jul 2022 → Mar 2024 | small cell lung carcinoma | Chipscreen Biosciences, Ltd. | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBCASERTIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095033 ↗ |
| Known as | Chiauranib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05497843 ↗ |
| Known as | CS-2164 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095033 ↗ |
| Action | Inhibit | “Chiauranib is a novel orally active multi-target inhibitor that simultaneously inhibits the angiogenesis-related kinases (VEGFR2, VEGFR1, VEGFR3, PDGFRα, and c-Kit),...” PMID 30642372 ↗ Jan 20191“Serine/threonine-protein kinase Aurora-B inhibitor” CHEMBL5095033 ↗ |
| Modality | Small molecule | “Chiauranib is a novel small-molecule selective inhibitor” PMID 39123210 ↗ Aug 2024 |
| Route | Oral | “Take orally” NCT02122809 ↗ |
| Target | AURKB | “Serine/threonine-protein kinase Aurora-B inhibitor” CHEMBL5095033 ↗ |